FILE - In this Friday, June 12, 2020 file photo, a doctor holds a bag of blood plasma donated by a COVID-19 survivor at at blood bank in La Paz, Bolivia. The U.S. Food and Drug Administration authorized the use of blood plasma for what’s called “emergency use” during the coronavirus pandemic, but the World Health Organization (WHO) on Monday AUG. 24, 2020, cautioned that using blood plasma from COVID-19 survivors to treat other patients is still considered an experimental therapy. (AP Photo/Juan Karita, FILE)

UN cautions that coronavirus plasma treatment still experimental

FDA’s action was announced by U.S. President Donald Trump, who called it a ‘breakthrough’

The World Health Organization on Monday cautioned that using blood plasma from COVID-19 survivors to treat other patients is still considered an experimental therapy, voicing the concern as a U.S. boost for the treatment has many scientists afraid formal studies will be derailed.

On Sunday, the U.S. Food and Drug Administration authorized what’s called “emergency use” of the treatment under its special powers to speed the availability of promising experimental drugs during a public health crisis. The action isn’t the same as approving plasma as safe and effective, and numerous rigorous studies are underway to find out if it really works.

So far, “The results are not conclusive,” WHO’s chief scientist Dr. Soumya Swaminathan said during a press briefing. “At the moment, it’s still very low-quality evidence.”

Convalescent plasma is a century-old treatment that was used to fight off flu and measles outbreaks in the days before vaccines, and was tried more recently during the Ebola outbreak. When the body encounters a new germ, it makes proteins called antibodies that are specially targeted to fight the infection. The antibodies float in plasma — the yellowish, liquid part of blood — which is collected from COVID-19 survivors and given to patients infected with coronavirus.

Swaminathan said WHO considered plasma therapy to be experimental and that it should continue to be evaluated. She said the treatment is difficult to standardize: Plasma must be collected individually, and people produce different levels of antibodies.

“Of course, countries can do an emergency listing if they feel the benefits outweigh the risks,” she said. “But that’s usually done when you’re waiting for the more definitive evidence.”

READ MORE: Trump announces plasma treatment authorized for COVID-19

In a letter describing the FDA’s emergency action, the agency’s chief scientist said the treatment “should not be considered a new standard of care” for coronavirus infections, and that more data from studies will be available in the coming months.

But already, so many COVID-19 patients have requested plasma rather than agreeing to be part of a research study that many scientists fear they won’t get a clear answer on whether the treatment really works — and if it does, how and when it should be used for the best outcomes.

Martin Landray, of the University of Oxford said that while the therapy offers “huge promise,” there was still no proof it works.

“There is a huge gap between theory and proven benefit,” he said in a statement.

If just a few thousand patients took part in the research “we would have the answer,” said Landray, who is conducting a plasma study in the U.K. “If effective, convalescent plasma could be rapidly used worldwide. If not, it could be abandoned,”

Stephen Griffin, an associate professor of medicine at the University of Leeds, said there was still considerable uncertainty about the immune system’s response to COVID-19, making any potential use of convalescent plasma challenging.

The FDA’s action was announced during a Sunday press briefing by U.S. President Donald Trump, who called it a “breakthrough.”

“It appears that the lessons from hydroxychloroquine have not been learned,” Griffin said, referring to the malaria drug touted by Trump and others as a potential treatment for the coronavirus.

The FDA also granted hydroxychloroquine an emergency authorization before suspending it months later after several trials showed the drug didn’t work against COVID-19 and raised the risk of heart, kidney, liver and other problems.

____

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.

Maria Cheng, The Associated Press


Like us on Facebook and follow us on Twitter.

Want to support local journalism during the pandemic? Make a donation here.

CoronavirusDonald TrumpUSA

Just Posted

Radium council discusses short term rentals

RHS council are elaborating the second draft plan for STR

Invermere gets new CAO

Invermere found his new CAO after a long period of research.

Doctor Creek fire finally ‘being held’

The wildfire in Canal Flats is under control

Mount Nelson Community Garden

The Community Garden in the Mount Nelson Athletic Park is now full of vegies, herbs and flowers.

KCP accepts proposal for Columbia Valley Local Conservation Fund

CVLCF will now provide financial support for local projects

VIDEO: B.C. to launch mouth-rinse COVID-19 test for kids

Test involves swishing and gargling saline in mouth and no deep-nasal swab

Record-breaking 165 new COVID-19 cases diagnosed in B.C. in 24-hour period

Fifty-seven people are in hospital battling the novel coronavirus

B.C. teachers file Labour Relations Board application over COVID-19 classroom concerns

The application comes as B.C.’s second week of the new school year comes to a close

Young Canadians have curtailed vaping during pandemic, survey finds

The survey funded by Heart & Stroke also found the decrease in vaping frequency is most notable in British Columbia and Ontario

B.C.’s COVID-19 economic recovery plan: Top 5 things you need to know

Jobs training, tax incentives for employers to hire staff and more

March to protect old growth, stop industrial logging coming to B.C. Legislature

Organizers say they want to give frontline communities a bigger say in nearby logging

B.C. releases details of $1.5B economic recovery plan, $660M in business tax incentives

Economic plan includes support for employers, as well as training for workers

‘Not criminally responsible’ hearing slated for man convicted of Abbotsford school stabbing

Gabriel Klein was found guilty in March of killing Letisha Reimer, 13, in 2016

Most Read